Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Taisho: Sales Flat, Ordinary and Net Profits Slip
December 9, 2002
- CORPORATE ROUNDUP NEWS IN BRIEF
December 9, 2002
- WORLD NEWS IN BRIEF
December 9, 2002
- Banyu: NHI Price Cuts, Higher R&D Spending Reduce Net Profits by 52.6%
December 9, 2002
- 14 New Drugs Including Micafungin to Be Included in NHI Price List
December 9, 2002
- SSP: Slump of OTC Drugs Affects Overall Performance
December 9, 2002
- Approval of Femara, IFN-a (Human Leukocytes) Withheld
December 9, 2002
- Kaken: 1st-half Sales, Profits Up Despite Downturn of Mainstays
December 9, 2002
- Chuikyo to Review NHI Re-pricing Rules
December 9, 2002
- Toyama Chemical: Sales Down 0.9% on Slump in Major Products
December 9, 2002
- Generics' Share Continues to Increase at National Hospitals
December 9, 2002
- Teikoku Hormone: Drug Sales Down 7.2% in First Half
December 9, 2002
- Korosho to Demand \21.7 Bil. for Science & Technology in Supplementary Budget
December 9, 2002
- Nippon Chemiphar: Uralyt Sales Strong but Less than Expected
December 9, 2002
- REGULATORY NEWS IN BRIEF
December 9, 2002
- Nikken Chemicals: Ethical Drug Sales Down 3.7% in 1st Half
December 9, 2002
- Kyowa Hakko to Collect Evidence on Coniel from Large Study
December 9, 2002
- Fukujin: Sales Up 14.2%, Profit Up 80.9%
December 9, 2002
- Matsumotokiyoshi: Sales Up 4.2%, Operating Profits Up 21%
December 9, 2002
- VITAL-NET: Sales Up, Operating Profits Jump
December 9, 2002
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…